AUCTORES
Globalize your Research
Research Article
*Corresponding Author: Robert G Smith, Shoe String Podiatry Ormond Beach, Florida, North America, USA.
Citation: Robert G Smith., (2020) Covid-19 Effects on the Medications Used to Treat Diabetes. J Pharmaceutics and Pharmacology Research 3(1); DOI:10.31579/2693-7247/008
Copyright: © 2020, Robert G Smith, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 07 August 2020 | Accepted: 19 August 2020 | Published: 25 August 2020
Keywords: Covid-19; Medications;Treat Diabetes
Minority patients taking prescription drugs for diabetes mellitus and hypertension are sick and vulnerable. They should not be subjected to poor quality medications that can make them worse. The purpose of this review is to present data fortifying an argument that Covid-19 will continue to disproportionally effect minorities who suffer with Type 2 Diabetes Mellitus, Hypertension, and GI ulcer disease by limiting drug safety for pharmaceuticals that are imported from oversea manufacturers even after the pandemic is over. As a foundation an overview of the Food and Drug Administration (FDA) overseas inspection process that have been validated by previously published reports will be offered to accent the procedural process. Limitations and challenges to the overseas drug inspection process as documented by congressional leadership and the FDA are offered. An accurate scientific description of N-nitrosodimethylamine (NDMA) will be presented to emphasize its danger to these patients. Five key points or initiatives recently published by the FDA to assist in food and drug safety from overseas manufacturers during the Covid-19 pandemic will be presented
The effects of COVID-19 on the health of racial and ethnic minority groups is still being studied. Data suggests a disproportionate burden of illness and death among racial and ethnic minority groups. A recent MMWR report included race and ethnicity data from hospitalized with lab-confirmed COVID-19 found that 45% of individuals for whom race or ethnicity data was available were white, compared to 59% of individuals in the surrounding community.1 However, 33% of hospitalized patients were black, compared to 18% in the community, and 8% were Hispanic, compared to 14% in the community. These data suggest an over-representation of blacks among hospitalized patients.1 Among the 178 adult study population had data consistent with having one or more underlying conditions described as the following: the most common were hypertension (49.7%), obesity (48.3%), chronic lung disease (34.6%), diabetes mellitus (28.3%), and cardiovascular disease (27.8%). [1] In the United States, 34.2 million or 10.5% of the total population have diabetes mellitus. [2] Among those aged 65 years or older, a population at higher risk for death from COVID-19, 26.8% have diabetes mellitus.[2] Muniyappa and Gubbi summarize that individuals with diabetes mellitus, hypertension, and severe obesity (BMI 40 kg/m2) are more likely to be infected and are at a higher risk for complications and death from COVID-19. [3] Gautam et al reported that diabetes mellitus has well known costly complications but wanted to show through a retrospective model that costs of care for chronic pain treated with opioid analgesic medications would also be substantial. [4] They found that higher costs of care for opioid-treated patients appeared for all types of services and likely reflects multiple factors including morbidity from the underlying cause of pain, care and complications related to opioid use, and poorer control of diabetes as found in other investigations. [4] Ethnic minority populations in the United States are disproportionately affected by cardiovascular disease (CVD) risk factors, including hypertension, overweight/obesity, and diabetes.[4,5] An attractive inference can be made that a clinician would utilize metformin, angiotensin II receptor blockers (ARBs), and H2 antagonists to treat these chronic conditions in a patient diagnosed with Type 2 diabetes mellitus. Given, this inference and the reality that N-nitrosodimethylamine (NDMA) has been detected in toxic levels by the Food and Drug Administration (FDA) in these pharmaceuticals allows for a concern to be voiced that these patients may be exposed to this carcinogen. The purpose of this review is to present data fortifying an argument that Covid-19 will continue to disproportionally effect minorities who suffer with Type 2 Diabetes Mellitus, Hypertension, and GI ulcer disease by limiting drug safety for pharmaceuticals that are imported from oversea manufacturers even after the pandemic is over. First, as a foundation an overview of the Food and Drug Administration (FDA) overseas inspection process that have been validated by previously publish will be offered to accent the procedural process. Secondly, limitations and challenges as documented by congressional leadership and the FDA agency itself as they are describing their overseas inspection process will be offered. Thirdly, an accurate scientific description of N-nitrosodimethylamine (NDMA) will be offered to emphasize its danger to these patients. Lastly, five key points or initiatives recently published by the FDA to assist in food and drug safety from overseas manufacturers during the Covid-19 pandemic will be offered.
A pharmaceutical manufacturer may be held liable for product defect if the product is unreasonably dangerous. Four basic elements define how a pharmaceutical product can be legally considered to be defective: (1) manufacturing defects, (2) warning defects, (3) design defects, and (4) marketing defects. Because pharmaceutical products are produced according to exacting standards, with close FDA (Food and Drug Administration) oversight and frequent facility inspections, it is rare for there to be a viable manufacturing defect case involving pharmaceutical products. FDA is responsible for overseeing the safety and effectiveness of all drugs marketed in the United States, regardless of where they are produced and conducts inspections of both foreign and domestic drug manufacturing establishments. Drug manufacturing defects to include the impurity “N-Nitrosodimethylamine” (NDMA) have been reported in a number of medications that are consumed by Type 2 diabetic patients: metformin, angiotensin II receptor blockers (ARBs), and H2 antagonists manufactured in foreign drug manufacturing plants.
As previously published Senate Finance Committee Chairman Chuck Grassley of Iowa sent a letter on August 7, 2019 to Department of Health and Human Services (HHS) Secretary and Food and Drug Administration (FDA) Acting Commissioner urging them to reinstate unannounced inspections of prescription drug manufacturing facilities in foreign countries in light of the administration’s new “Safe Importation Action Plan” as well as the fact that these facilities provide most of the ingredients for production inside the United States. Therefore, it is important to determine more accurately if these facilities meet set standards of quality and safety for both domestic and importation purposes. [6,7] Further, Grassley’s published letter high-lighted that the FDA in 2014 unveiled a pilot program in India, the senator noted, that cut out advance notice of an inspection in lieu of either short notice or an unannounced visit. [6] Grassley describes that this program also provided that FDA inspectors arrange their travel through U.S. embassies versus FDA offices or manufacturer-arranged travel so there was more secrecy ahead of an inspection.[6] Under that program, the FDA saw a 60% increase in the number of warnings it issued to manufacturers, he said. In 2015 this pilot program ended. [6,7] In defense to Senator Grassley’s letter Stephen M. Hahn, Commissioner of Food and Drugs wrote and published to Senator Grassley’s letter with a response letter dated February 12, 2020 that describes the: Notice of Proposed Rulemaking (NPRM) with its two pathways published on December 23, 2019.[8]
Of interest is that the United States increase dependency on foreign manufacturers for prescription and generic drugs, the Food and Drug Administration is plagued with the problem of conducting overseas inspections of drug manufacturing plants is gaining attention. As recently as May 2020, it has been reported that only 26 percent of facilities manufacturing active pharmaceutical ingredients and a minority of 46 percent of the facilities producing finished dosage forms for human drug consumption for the U.S. market were actually in U.S.[9] Drugs manufactured overseas must meet the same statutory and regulatory requirements as those manufactured in the United States. FDA’s Center for Drug Evaluation and Research (CDER) establishes standards for the safety, quality, and effectiveness of, and manufacturing processes for, over the counter and prescription drugs. CDER requests that FDA’s Office of Regulatory Affairs (ORA) inspect both domestic and foreign establishments to ensure that drugs are produced in conformance with applicable laws of the United States, including current good manufacturing practice (CGMP) regulations. [9] FDA investigators generally conduct three main types of drug manufacturing establishment inspections: preapproval inspections, surveillance inspections, and for-cause inspections. [9] The Trump administration announced the formerly-bankrupt, half-dead company, Eastman Kodak, will collect a $765 million federal loan to transform itself into a pharmaceutical manufacturing company, making ingredients for use in generic drugs to alleviate America’s dependency on foreign counties for pharmaceuticals.
From 2012 to 2016, the FDA did increase the number of foreign inspections it conducted. [9] The number of inspections of foreign drug manufacturers has declined since fiscal year 2016, which the FDA attributes in part to fewer inspectors and difficulty filling jobs abroad. Most foreign inspections are preannounced, giving manufacturers time to prepare for inspections.[9] The FDA does conduct surprise foreign inspections, but not many, and the exact number is not known, per Mary Denigan-Macauley, the Governmental Accounting Office Health Care Director.[9] Further, despite calls for more inspections, both foreign and domestic inspections decreased by 10 percent and 13 percent respectively from fiscal 2016 through fiscal 2018.[9]
The FDA offers documentation that in 2010, 64% of foreign manufacturing plants, predominantly in India and China, had never been inspected by the FDA.[9,10] Alarmingly by the year 2015, 33% of these plants still remained uninspected.[9,10] The U.S. Food and Drug Administration has struggled for more than a decade with language barriers when inspecting foreign drug manufacturing facilities and frequently relies on translators provided by the companies under examination, raising questions about impartiality and accuracy of information, a government investigator told lawmakers.[10-14] The FDA inspections are riddled with problems because the FDA admittedly doesn’t have enough translators, inspectors are often forced to rely on the drug manufacturer to provide reports that can raise questions about the accuracy of information FDA investigators collect. [10-14] The FDA admits that generally it does not send translators on inspections in foreign countries. FDA investigators rely on the pharmaceutical industries to provide translation services, which can be an English-speaking employee of the industry being inspected, an external translator hired by the industry, or an English-speaking consultant hired by the industry [10-14]. This may not be big problem in India but it may be challenging in parts of Asia, including China and Japan [10-14]. Unlike domestic inspections, which are all unannounced, the vast majority of overseas firms have months of advance warning of an FDA visit, giving them plenty of time to prepare. [10-14]
In Eban’s previously published works describes tactics and examples that foreign pharmaceutical manufacturers have done to avoid being inspected by the FDA. [15] First. Inspectors discovered that vials made by Wockhardt had tested contained black metallic particles which came from defective sterilizing equipment and were potentially deadly and had failed visual inspection. [15] The investigators followed documents that uncovered a formulation area that had not disclosed to the FDA, where the company was using corroded sterilizing equipment to make both insulin and injectable adenosine.[15]
Another example Eban describes took place in a facility in West Bengal, India, that manufactured chemotherapy drugs for the German pharmaceutical company Fresenius Kabi Oncology.[15] The investigators discovered not all the plant’s files, were stored on its main server making it difficult to conduct a complete inspection. [15] Moreover, Eban asserts and describes another example of FDA investigators visiting a facility in Punjab, India, where Ranbaxy Laboratories made atorvastatin calcium.15 According to the inspection report, in the quality-control laboratory, they found dozens of workers hunched over documents and back dating them.15 Also, while inspectors examined the plant’s computer systems, they discovered even more consequential falsifications. [15]
Another incident describes FDA investigators showed up unannounced at an Akorn India facility in Himachal Pradesh.[15] The testing data appeared to be in perfect order; data worksheets in the microbiology laboratory showed that samples had been prepared, incubated, and examined but these samples were not presented to the investigators.15 An additional incident describes FDA investigators visit to a facility in Punjab, India, run by Parabolic Drugs.[15] During the inspection, an investigator claimed to have found a filthy, small, locked laboratory, its entrance partially blocked by a piece of bulky equipment.15 Also, some of those test results were not entered into the plant’s official data system, which, the inspectors wrote, was “necessary to assure compliance. [15]
Another of Eban’s example where FDA investigators visited a Mylan Laboratories facility in Nashik, Maharashtra, after a whistleblower claimed that employees were deliberately corrupting data.[15] Upon inspection it was discovered that the plant’s software system was riddled with error messages.[15] Plant managers had apparently conducted no investigation into the repeated crashes.[15] The FDA suspected that the crashes had been intentional, just as the whistleblower had alleged.[15]
Eban illuminates another published account where FDA investigators visited a facility in northeastern China run by Zhejiang Hisun, the country’s largest exporter of pharmaceutical ingredients to the United States.[15] At the plant’s quality-control laboratory, an investigator searched the grid of computer audit trails and figured out that the plant was secretly pretesting its drug samples and masking the results.[15] In one instance, the FDA claims, technicians had disabled the audit trail, run 80 covert tests, then turned the trail back on two days later.[15]
The last example is as well as the most outrageous described by Eban published account occurred while on an inspection to a facility in northeastern China where Zhejiang Bangli Medical Products manufactured lidocaine and capsaicin skin patches for treating pain.15 Soon after the investigator and her translator began their work, worried company officials started interrogating them and questioning their authority to inspect.[15] After the firm’s general manager became visibly upset, the inspectors went to gather their things in the conference room. The general manager refused to let them leave, effectively imprisoning them, and called the police, who, according to the FDA, claimed their credentials were fake.[15] More than an hour later, after the intercession of Chinese drug regulators, the FDA employees were finally freed.
Lastly according to Eban’s published reporting, the FDA downgraded recommended sanctions against Indian plants 109 times between 2013 and 2018.[15] Further, Eban has asserted: “The FDA is knowingly allowing unsafe, substandard drugs from noncompliant plants into the U.S., over the recommendations of its own investigators.” [15]
N-nitrosodimethylamine (NDMA)
Over the last decade relation to N-Nitrosodimethylamine (NDMA) found in water and wastewater has been reported. Chloramination is the most common process that results in formation of NDMA during water and wastewater treatment. However, ozonation of wastewater or highly contaminated surface water can also generate significant levels of NDMA.16 White has reported and published that N-nitrosodimethylamine (NDMA) is a hepatotoxic agent and carcinogen contaminant in commonly used medications such as valsartan, losartan, irbesartan, and ranitidine.[17] It can be argued that a patient suffering from Type 2 diabetes is more at risk for hepatotoxicity from the impurity NDMA because of the pathogenesis of Type 2 diabetes mellitus. The Food and Drug Administration has established a maximum dose of NDMA that is permissible per tablet and guidance for manufacturers. White has taken the position through his publications that many unanswered questions about NDMA contamination facilitates the need for rigorous FDA investigation. [17] According to FDA communications the acceptable human daily intake of NDMA is 96 nanograms or 0.32 parts per million. NDMA can be found in medications from the drug’s manufacturing process, the medication’s chemical structure, or storage or packaging conditions. [18]
NDMA was one of several nitrosamine impurities implicated massive product recalls because the population at risk of exposure has vastly increased allowing for minority populations to be greatly effective from inaction. In April 2020, the FDA required the removal of all ranitidine products from the market after it was discovered that NDMA levels could increase over time under normal storage conditions and that higher levels were associated with products that had a longer length of time since they were manufactured. [18, 19] In addition, NDMA was found to increase significantly in ranitidine samples stored at higher temperatures. Specifically, unacceptable levels of this potentially carcinogenic impurity have been identified in products manufactured by 5 different firms that the FDA is working with these manufacturers to begin recalls. [18,19] Lastly, fortunately not present in samples of the plain metformin active, elevated levels of NDMA Have been found in finished-dose tablets of the Metformin ER formulation. [18, 19]
The COVID-19 pandemic has brought some challenges to the FDA yet the agency has stated they continue to utilize and implement additional alternative inspection tools and approaches while postponing foreign and domestic routine surveillance facility inspections.[9] This will continue as conditions warrant, except for certain mission critical inspections, including pre-approval and for-cause assignments.[9] As a result of the COVID-19 pandemic, most foreign and domestic surveillance facility inspections are currently postponed.[9] Only inspections deemed mission critical will be considered on a case-by-case basis as this outbreak continues to unfold. The FDA announced it will employ additional tools to ensure the safety of products imported to the U.S., which have proved effective in the past.[9] These will include: denying entry of unsafe products into the U.S.; physical examinations and/or product sampling at the U.S. borders; reviewing a firm’s previous compliance history; using information sharing from foreign governments as part of mutual recognition and confidentiality agreements; and requesting records “in advance of or in lieu of” on-site drug inspections.[9] Five key points that were accentuated during the June 2, 2020, the U.S. Senate Committee on Finance held hearing centered on FDA’s oversight of the global pharmaceutical supply chain included: the FDA stands behind the agency’s foreign inspection practices, the FDA is under pressure to increase unannounced foreign inspections, the FDA believes “alternative tools” are adequate to ensure the quality of foreign manufactured drugs during the COVID-19 pandemic, the FDA offered no indication as to when it will resume international drug inspections, and there is a clear push for more domestic drug manufacturing and solutions to drug shortages [9].
Fifty years ago, the pharmaceutical industry moved away from the United States traveled first to Puerto Rico in response to tax incentives, and then to Europe and nations that were developing at the time, such as China and India. Therefore, the clear push for more domestic drug manufacturing to be the solution to drug shortages lacks any financial incentives for pharmaceutical companies to return to the United States. The return of drug manufacturing to the United States is a clear challenge for the FDA. Secondly, the FDA is under pressure to increase unannounced foreign inspections, given the current pandemic this is a significant challenge for the FDA and is unlikely. The FDA believes that “alternative tools” will be adequate to ensure the quality of foreign manufactured drugs during the COVID-19 pandemic, this belief is centered on creative magical thinking. Given, that announced FDA foreign inspections were confronted with obstacles to the point of holding an inspector hostage. It is unlikely that alternative tools to ensure the safety of the United States drug supply chain can take the place of unannounced FDA foreign inspections. The current COVID-19 pandemic will curtail unannounced foreign inspections especially given that the lack of FDA employees willing to perform foreign drug supplier inspections exist. The lack of key employees to perform inspections will result in more medication contamination that will affect the diabetic patient because an honor system will ultimately fail.
Minority patients taking prescription drugs for diabetes mellitus and hypertension are sick and vulnerable; they should not be subjected to poor quality medications that can make them worse. It is expensive, logistically challenging, and politically unpalatable for the FDA to show up for unannounced inspections of foreign drug manufacturing plants. If the FDA is not given funding to increase testing of foreign medications, it should not be subject United States citizens to the potential impurities and contaminates in the United States drug supply chain. Only with proactive FDA approach to ensure the United States drug supply will become the safest in the world.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
